- Promising results from the EMAGINE randomized trial
suggest that treatment with BRAIN.Q's AI-powered low
electromagnetic field stimulation, aimed at enhancing the brain's
ability to relearn processes lost after a stroke, may help patients
regain 'freedom from disability' with greater
likelihood.
- First-ever use of a wearable cloud-connected therapeutic
system with a moderate to severe impaired
stroke population, demonstrating the feasibility of autonomous use
at home by patients and their caregivers, as well as a very high
safety profile.
- The novel technology has received FDA Breakthrough Device
Designation, and the company expects to obtain a CE Mark in the
coming year.
- Clinical trial results were presented by Dr. Jeffrey Saver, Director of Stroke at
UCLA, as Late Breaking Science at the
European Stroke Conference (ESOC) plenary session.
JERUSALEM, May 16, 2024
/PRNewswire/ -- BRAIN.Q, an emerging leader in
AI-driven Brain
Longevity Therapeutics
today announced promising results from its U.S. multicenter
randomized controlled study - EMAGINE, suggesting that treatment
with its AI-powered electromagnetic field therapy may lead to
meaningful clinical benefits and a substantial reduction in
disability following a stroke. These promising results align with
the encouraging findings observed in an earlier randomized
controlled pilot trial done with BRAIN.Q's therapy, announced in
2021.
In the trial, conducted at 15 leading U.S. academic
centers, the brain stimulation therapy targeted
moderate to severe ischemic stroke patients and
was conducted as a daily session in the weeks following stroke.
Although not reaching statistical significance, results suggested
that patients receiving the treatment are more likely to have a
greater reduction in their disability levels following the stroke
compared to patients in the
control group.
Findings suggested that actively treated patients were
also more than twice as likely to be free from disability at 3
months – implying going back to live independently, returning to
work, social activities, and hobbies.
The promising results were announced today by Dr.
Jeffrey L. Saver, Director of Stroke
at UCLA and the National Co-Principal
Investigator for the EMAGINE study, as a Late Breakthrough Science
at the European Stroke Conference (ESOC). "In the past several
decades we have made tremendous progress in emergency stroke
treatments that reduce, but do not fully prevent, brain injury,"
says Dr. Saver, "but we have had limited success in developing
therapies that can meaningfully reverse the life-debilitating
disabilities still often caused by stroke. The welcome results from
this study suggest there is a chance that even severe stroke
patients may be able to regain freedom from disability with this
therapy." In the trial, the brain stimulation therapy also showed
an excellent safety profile, with a limited number of adverse
events and with no serious adverse events related to the therapy.
BRAIN.Q relies on emerging science suggesting the use of targeted
stimulation of brain network activity as a key to maximizing the
brain's learning capabilities. The company uses AI to analyze
datasets of brain network activity and mirror them back to patients
to maximize their recovery.
This is also the first-ever use of a wearable
cloud-connected therapeutic system with a severely impaired stroke
population, designed to address the patient's fragmented pathway
from hospital to home. The company reports a striking ~90%
adherence rate to treatments by the patients, with over 2,500
sessions performed successfully autonomously by the patient and
their caregiver at home.
"Millions of stroke survivors worldwide endure
life-altering disabilities. The EMAGINE trial results mark a big
step towards a therapy that can help these patients reclaim their
lives, all from the comfort of their homes," said Yotam Drechsler, CEO of BRAIN.Q.
The company will be launching this summer a U.S pivotal
trial EMAGINE 2.0, applying the next-generation technology, and is
expecting to receive a CE Mark approval later this year.
About BRAIN.Q: A privately
held US-Israeli based startup and emerging leader in AI-driven
brain longevity therapeutics, is dedicated to developing innovative
solutions that change the lives of patients suffering from
neurological disorders. The company has received Breakthrough
Device Designation by the FDA. For more information
visit: https://brainqtech.com/.
PRESS CONTACT:
Leah Stern
Partner, Global Communications @OurCrowd
UK:
+44-747-019-6826
US: +1-646-568-9916
ISRAEL:
+972-2-560-9486
E: leah@ourcrowd.com
Photo - https://mma.prnewswire.com/media/2415039/BrainQ.jpg
View original content to download
multimedia:https://www.prnewswire.com/news-releases/results-from-brainqs-emagine-study-on-the-use-of-ai-powered-electromagnetic-field-therapy-offer-hope-for-meaningful-recovery-following-stroke-302147869.html
SOURCE BrainQ